Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07AZB
|
||||
Former ID |
DPR000180
|
||||
Drug Name |
ISIS-PTP1B
|
||||
Drug Type |
Antisense drug
|
||||
Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Preclinical | [551052] | ||
Company |
ISIS Pharm
|
||||
Target and Pathway | |||||
Target(s) | mRNA of Protein tyrosine phosphatase-1B | Target Info | [551052] | ||
KEGG Pathway | Adherens junction | ||||
Insulin signaling pathway | |||||
NetPath Pathway | FSH Signaling Pathway | ||||
PANTHER Pathway | Cadherin signaling pathway | ||||
Pathway Interaction Database | Insulin Pathway | ||||
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||||
Signaling events mediated by PTP1B | |||||
Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
Signaling events mediated by TCPTP | |||||
IGF1 pathway | |||||
EGF receptor (ErbB1) signaling pathway | |||||
Posttranslational regulation of adherens junction stability and dissassembly | |||||
PDGFR-beta signaling pathway | |||||
N-cadherin signaling events | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.